Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer

Molecular Medicine Reports
Yan ZhouXiao-An Li

Abstract

The use of a bispecific antibody (BsAb) is a promising and highly specific approach to cancer therapy. In the present study, a fully human recombinant single chain variable fragment BsAb against human epidermal growth factor receptor (HER)2 and cluster of differentiation (CD)3 was constructed with the aim of developing an effective treatment for breast cancer. HER2/CD3 BsAb was expressed in Chinese hamster ovary cells and purified via nickel column chromatography. Flow cytometry revealed that the HER2/CD3 BsAb was able to specifically bind to HER2 and CD3‑positive cells. HER2/CD3 BsAb was able to stimulate T-cell activation and induce the lysis of cultured SKBR‑3 and BT474 cells in the presence of unstimulated T lymphocytes. HER2/CD3 BsAb efficiently inhibited the growth of breast cancer tissue by activating and inducing the proliferation of tumor tissue infiltrating lymphocytes. Therefore, HER2/CD3 BsAb is a potent tool which may be a suitable candidate for the treatment of breast cancer.

References

Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Sep 2, 2004·Cancer Chemotherapy and Biological Response Modifiers·Richard S Finn, Dennis J Slamon
Jul 30, 2005·Molecular Endocrinology·Marco ContiYou-Qiang Su
Sep 13, 2005·Breast Cancer Research and Treatment·Chun-Xia WangMichael P Digiovanna
Oct 11, 2005·Drug Discovery Today·Evelyn WolfPatrick A Baeuerle
Oct 21, 2005·The New England Journal of Medicine·Harold J Burstein
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ursula ReuschLawrence G Lum
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christel LarbouretDavid Azria
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Richard StebbingsStephen Poole
Dec 12, 2007·Handbook of Experimental Pharmacology·H M ShepardD C Maneval
Jan 28, 2012·Biochimica Et Biophysica Acta·Joep P J de HoonVivianne C G Tjan-Heijnen
Jul 7, 2012·The Breast : Official Journal of the European Society of Mastology·Nagi S El Saghir, Benjamin O Anderson
Mar 9, 2013·Clinical Medicine Insights. Oncology·Erik J BlokCornelis Fm Sier

❮ Previous
Next ❯

Citations

Mar 27, 2018·The Journal of Pharmacy and Pharmacology·Shima Moradi-KalbolandiLeila Farahmand
Sep 22, 2017·Journal of Hematology & Oncology·Shengnan YuKongming Wu

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
transfection
fluorescence-activated cell sorting
flow cytometry
chip
FCS

Software Mentioned

SPSS

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.